PlainPharmaWatch

CMS Open Payments · Program Year 2024

Avyxa Pharma, LLC

Avyxa Pharma, LLC reported $17,196.19 across General Payments, Research, and Ownership to 40 physicians and teaching hospitals across 40 transactions.

See the rankings → How this is sourced
$17.2K
All-tracks total
40
Transactions
40
Recipients
#1561
of 1,925 companies

Avyxa Pharma, LLC reported $17,196.19 across all CMS Open Payments tracks (General + Research + Ownership) to 40 physicians and teaching hospitals in Program Year 2024 - ranking #1561 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $17,196.19, averaging $429.90 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer avyxa-pharma-llc Avyxa Pharma, LLC

$17.2K · #1561/1,925 · 0.0% industry · PY2024

  • TOT $17.2K
  • RANK #1561
  • SHARE 0.0%
  • TXN 40
  • RCP 40
  • CAT 3
  • GEN $17.2K
  • TOP1 29.1%
  • PY 2024

Volume peers

Nearest volume peer: Rattan And Associates ($17.3K)

Helios Cardio Inc$17.4KPromega Corporation$17.3KAfaxys, Inc.$17.3KRattan And Associates$17.3KAvyxa Pharma, LLC (this)$17.2K
All-tracks payment totals near Avyxa Pharma, LLC (CMS Open Payments PY2024)

Avyxa Pharma, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Avyxa Pharma, LLC

$17,196.19: that is what Avyxa Pharma, LLC reported in payments to 40 physicians and teaching hospitals during Program Year 2024, spread across 40 transactions ($429.90 per transaction, $429.90 per recipient). The company sits at rank #1561 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $10.0K, accounting for 58.2% of this company's General Payments and 4 transactions.

General Payment Breakdown by Type

Avyxa Pharma, LLC made 3 types of general payments. "Consulting Fee" is the largest category at $10.0K, 58.2% of General Payments.

How Avyxa Pharma, LLC divides its payments

How the reported total splits across payment categories

1. Consulting Fee$10.0K2. Honoraria$4.0K3. Food and Beverage$3.2K
Payment Type Amount Transactions
Consulting Fee $10.0K 4
Honoraria $4.0K 4
Food and Beverage $3.2K 32

Recipient Concentration in General Payments

The five largest recipient relationships account for $13,000.00 (75.6%) of $17,196.19 in this company's General Payments records across 38 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Avyxa Pharma, LLC

The five named recipients with the highest reported General Payments from this company

Vikram Gorantla$5.0KMohit Narang$5.0KSalim Contractor$1.0KRussell Gollard$1.0KGang Tian$1.0K
  1. 1

    Vikram Gorantla

    $5,000.00 across 2 reported transactions

  2. 2

    Mohit Narang

    $5,000.00 across 2 reported transactions

  3. 3

    Salim Contractor

    $1,000.00 across 1 reported transactions

  4. 4

    Russell Gollard

    $1,000.00 across 1 reported transactions

  5. 5

    Gang Tian

    $1,000.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Avyxa Pharma, LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Avyxa Pharma, LLC.

Amarin Pharma Inc.

HHI 1855

HydroCision, Inc.

HHI 1854

Canary Medical USA LLC

HHI 1873

C. R. Bard, Inc. & Subsidiaries

HHI 1853

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Avyxa Pharma, LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Avyxa Pharma, LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.